Brian K Law

List of Publications by Year
in descending order

69	2,272	201674	223800
papers	citations	27 h-index	46 g-index

76	76	76	4343
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Rapamycin: An anti-cancer immunosuppressant?. Critical Reviews in Oncology/Hematology, 2005, 56, 47-60.	4.4	223
2	A novel ATG4B antagonist inhibits autophagy and has a negative impact on osteosarcoma tumors. Autophagy, 2014, 10, 2021-2035.	9.1	190
3	Apratoxin A Reversibly Inhibits the Secretory Pathway by Preventing Cotranslational Translocation. Molecular Pharmacology, 2009, 76, 91-104.	2.3	129
4	Anticolon Cancer Activity of Largazole, a Marine-Derived Tunable Histone Deacetylase Inhibitor. Journal of Pharmacology and Experimental Therapeutics, 2010, 335, 351-361.	2.5	106
5	Rapamycin Potentiates Transforming Growth Factor Î²-Induced Growth Arrest in Nontransformed, Oncogene-Transformed, and Human Cancer Cells. Molecular and Cellular Biology, 2002, 22, 8184-8198.	2.3	102
6	The unfolded protein response as a target for anticancer therapeutics. Critical Reviews in Oncology/Hematology, 2018, 127, 66-79.	4.4	102
7	Small-Molecule Inhibitors of Acetyltransferase p300 Identified by High-Throughput Screening Are Potent Anticancer Agents. Molecular Cancer Therapeutics, 2013, 12, 610-620.	4.1	88
8	Cyclin-Dependent Kinase Inhibitors as Anticancer Therapeutics. Molecular Pharmacology, 2015, 88, 846-852.	2.3	79
9	Salicylate-induced Growth Arrest Is Associated with Inhibition of p70s6k and Down-regulation of c-Myc, Cyclin D1, Cyclin A, and Proliferating Cell Nuclear Antigen. Journal of Biological Chemistry, 2000, 275, 38261-38267.	3.4	75
10	SERPINE1: A Molecular Switch in the Proliferation-Migration Dichotomy in Wound-â€œActivatedâ€• Keratinocytes. Advances in Wound Care, 2014, 3, 281-290.	5.1	67
11	Rapamycin Disrupts Cyclin/Cyclin-Dependent Kinase/p21/Proliferating Cell Nuclear Antigen Complexes and Cyclin D1 Reverses Rapamycin Action by Stabilizing These Complexes. Cancer Research, 2006, 66, 1070-1080.	0.9	63
12	Loss of sirtuin 1 and mitofusin 2 contributes to enhanced ischemia/reperfusion injury in aged livers. Aging Cell, 2018, 17, e12761.	6.7	60
13	Î±B-Crystallin, an Effector of Unfolded Protein Response, Confers Anti-VEGF Resistance to Breast Cancer via Maintenance of Intracrine VEGF in Endothelial Cells. Molecular Cancer Research, 2011, 9, 1632-1643.	3.4	59
14	Epithelial-to-mesenchymal transition confers pericyte properties on cancer cells. Journal of Clinical Investigation, 2016, 126, 4174-4186.	8.2	59
15	Lessons From the First Comprehensive Molecular Characterization of Cell Cycle Control in Rodent Insulinoma Cell Lines. Diabetes, 2008, 57, 3056-3068.	0.6	52
16	Construction of a Cyclin D1-Cdk2 Fusion Protein to Model the Biological Functions of Cyclin D1-Cdk2 Complexes. Journal of Biological Chemistry, 2004, 279, 47688-47698.	3.4	49
17	Identification of novel Smad2 and Smad3 associated proteins in response to TGFâ€Î²1. Journal of Cellular Biochemistry, 2008, 105, 596-611.	2.6	49
18	A metabolic switch in proteasome inhibitor-resistant multiple myeloma ensures higher mitochondrial metabolism, protein folding and sphingomyelin synthesis. Haematologica, 2019, 104, e415-e419.	3.5	48

#	Article	IF	Citations
19	Farnesyltransferase Inhibitor Induces Rapid Growth Arrest and Blocks p70s6k Activation by Multiple Stimuli. Journal of Biological Chemistry, 2000, 275, 10796-10801.	3.4	42
20	The Malignant Brain Tumor (MBT) Domain Protein SFMBT1 Is an Integral Histone Reader Subunit of the LSD1 Demethylase Complex for Chromatin Association and Epithelial-to-mesenchymal Transition. Journal of Biological Chemistry, 2013, 288, 27680-27691.	3.4	42
21	VEGFR inhibitors upregulate CXCR4 in VEGF receptor-expressing glioblastoma in a TGFÎ²R signaling-dependent manner. Cancer Letters, 2015, 360, 60-67.	7.2	39
22	The B56Î³3 Regulatory Subunit of Protein Phosphatase 2A (PP2A) Regulates S Phase-specific Nuclear Accumulation of PP2A and the G1 to S Transition. Journal of Biological Chemistry, 2010, 285, 21567-21580.	3.4	35
23	Amino Acid Asp181 of 5â€²-Flap Endonuclease 1 Is a Useful Target for Chemotherapeutic Development. Biochemistry, 2009, 48, 9952-9958.	2.5	34
24	Targeted Inhibition of PAI-1 Activity Impairs Epithelial Migration and Wound Closure Following Cutaneous Injury. Advances in Wound Care, 2015, 4, 321-328.	5.1	31
25	Grassystatins Dâ€“F, Potent Aspartic Protease Inhibitors from Marine Cyanobacteria as Potential Antimetastatic Agents Targeting Invasive Breast Cancer. Journal of Natural Products, 2017, 80, 2969-2986.	3.0	31
26	Hematopoietic- and neurologic-expressed sequence 1 (Hn1) depletion in B16.F10 melanoma cells promotes a differentiated phenotype that includes increased melanogenesis and cell cycle arrest. Differentiation, 2009, 78, 35-44.	1.9	28
27	NSC666715 and Its Analogs Inhibit Strand-Displacement Activity of DNA Polymerase Î² and Potentiate Temozolomide-Induced DNA Damage, Senescence and Apoptosis in Colorectal Cancer Cells. PLoS ONE, 2015, 10, e0123808.	2.5	28
28	Mammary Tumors Initiated by Constitutive Cdk2 Activation Contain an Invasive Basal-like Component. Neoplasia, 2008, 10, 1240-1252.	5.3	27
29	An in vivo model of epithelial to mesenchymal transition reveals a mitogenic switch. Cancer Letters, 2012, 326, 183-190.	7.2	26
30	Development of an anti-angiogenic therapeutic model combining scAAV2-delivered siRNAs and noninvasive photoacoustic imaging of tumor vasculature development. Cancer Letters, 2013, 332, 120-129.	7.2	26
31	Kempopeptin C, a Novel Marine-Derived Serine Protease Inhibitor Targeting Invasive Breast Cancer. Marine Drugs, 2017, 15, 290.	4.6	26
32	CUB domain-containing protein 1 and the epidermal growth factor receptor cooperate to induce cell detachment. Breast Cancer Research, 2016, 18, 80.	5.0	25
33	Tumors Initiated by Constitutive Cdk2 Activation Exhibit Transforming Growth Factor Î² Resistance and Acquire Paracrine Mitogenic Stimulation during Progression. Cancer Research, 2007, 67, 3135-3144.	0.9	22
34	A Novel Class of Cyclin-dependent Kinase Inhibitors Identified by Molecular Docking Act through a Unique Mechanism. Journal of Biological Chemistry, 2009, 284, 29945-29955.	3.4	18
35	Identification of genes, including the gene encoding p27Kip1, regulated by serine 276 phosphorylation of the p65 subunit of NF-ÎºB. Cancer Letters, 2009, 275, 139-149.	7.2	18
36	Identification of a small molecule inhibitor of serine 276 phosphorylation of the p65 subunit of NF-ÎºB using in silico molecular docking. Cancer Letters, 2010, 291, 217-224.	7.2	18

#	Article	IF	Citations
37	Assembly, Activation, and Substrate Specificity of Cyclin D1/Cdk2 Complexes. Biochemistry, 2013, 52, 3489-3501.	2.5	18
38	Constitutive Cdk2 activity promotes aneuploidy while altering the spindle assembly and tetraploidy checkpoints. Journal of Cell Science, 2013, 126, 1207-1217.	2.0	17
39	In pursuit of new anti-angiogenic therapies for cancer treatment. Frontiers in Bioscience - Landmark, 2011, 16, 803.	3.0	16
40	Interaction between APC and Fen1 during breast carcinogenesis. DNA Repair, 2016, 41, 54-62.	2.8	16
41	ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells. European Journal of Medicinal Chemistry, 2019, 161, 456-467.	5.5	13
42	NSC30049 inhibits Chk1 pathway in 5-FU-resistant CRC bulk and stem cell populations. Oncotarget, 2017, 8, 57246-57264.	1.8	13
43	Disulfide bond disrupting agents activate the unfolded protein response in EGFR- and HER2-positive breast tumor cells. Oncotarget, 2017, 8, 28971-28989.	1.8	11
44	The Basic Helixâ€Loopâ€Helix/Leucine Zipper Transcription Factor USF2 Integrates Serumâ€Induced PAIâ€1 Expression and Keratinocyte Growth. Journal of Cellular Biochemistry, 2014, 115, 1840-1847.	2.6	10
45	Disulfide bond-disrupting agents activate the tumor necrosis family-related apoptosis-inducing ligand/death receptor 5 pathway. Cell Death Discovery, 2019, 5, 153.	4.7	9
46	A novel proteotoxic combination therapy for EGFR+ and HER2+ cancers. Oncogene, 2019, 38, 4264-4282.	5.9	8
47	Repurposing Tranexamic Acid as an Anticancer Agent. Frontiers in Pharmacology, 2021, 12, 792600.	3.5	4
48	Inhibitors of ERp44, PDIA1, and AGR2 induce disulfide-mediated oligomerization of Death Receptors 4 and 5 and cancer cell death. Cancer Letters, 2022, 534, 215604.	7.2	4
49	Signaling Mechanisms that Suppress the Cytostatic Actions of Rapamycin. PLoS ONE, 2014, 9, e99927.	2.5	3
50	Sensitization of FOLFOX-resistant colorectal cancer cells via the modulation of a novel pathway involving protein phosphatase 2A. IScience, 2022, 25, 104518.	4.1	3
51	Inhibition of cotranslational translocation by apratoxin S4: Effects on oncogenic receptor tyrosine kinases and the fate of transmembrane proteins produced in the cytoplasm. Current Research in Pharmacology and Drug Discovery, 2021, 2, 100053.	3.6	2
52	Epithelialâ€“Mesenchymal Transition Suppresses AMPK and Sensitizes Cancer Cells to Pyroptosis under Energy Stress. Cells, 2022, 11, 2208.	4.1	2
53	Transforming Growth Factor-Î² and Cancer. , 2007, , 91-111.		1
54	Abstract 447: A novel proteotoxic combination therapy for EGFR+ and HER2+ cancers. , 2018, , .		1

#	Article	IF	Citations
55	Anticancer Agents Derived from Cyclic Thiosulfonates: Structureâ€Reactivity and Structureâ€Activity Relationships. ChemMedChem, 2022, 17, .	3.2	1
56	Sensitization of FOLFOX-Resistant Colorectal Cancer Cells via the Modulation of a Novel Pathway Involving Protein Phosphatase 2A. SSRN Electronic Journal, 0, , .	0.4	0
57	Novel Cdk inhibitors identified by in silico screening act through a novel mechanism. FASEB Journal, 2009, 23, 756.17.	0.5	0
58	Abstract A17: Transforming growth factor beta stimulates STAT3 tyrosine phosphorylation and cellular invasion through interleukinâ€6 in human breast cancer cell lines. , 2009, , .		0
59	Abstract 3881: A novel class of structure-based cyclin-dependent kinase inhibitors. , 2010, , .		0
60	Abstract 2951: Regulation of E2F-dependent transcription by the mTORC1 pathway. , 2011, , .		0
61	Abstract 2943: Targeting the E2F pathway in cancer chemotherapeutics. , 2011, , .		0
62	Abstract 2895: The epithelial to mesenchymal transition is associated with alterations in the mitogenic signaling pathways that drive cancer cell proliferation. , 2011, , .		0
63	Abstract 3923: Constitutive Cdk2 activation results in endoreduplication, failed cytokinesis, and chromosomal instability. , 2011, , .		0
64	Abstract A71: Cdk2, Mad2, and the tetraploidy checkpoint in paclitaxel-induced endoreduplication.. , 2011, , .		0
65	Abstract 571: Overactive Cdk2 permits polyploidy by overwhelming the tetraploidy checkpoint.. , 2013, , .		0
66	Abstract PR16: A new class of small molecule acetyltransferase inhibitors discovered through high-throughput screening are potent anticancer agents with cancer-type specific activity. , 2013, , .		0
67	CDCP1. , 2014, , 854-857.		0
68	Abstract 4050: Multifaceted targeting of drug-resistant EGFR+ and HER2+ breast tumors. , 2017, , .		0
69	Cyclin-Dependent Kinases as Therapeutic Targets. , 2021, , 505-507.		0